Figure 5. Secondary efficacy outcomes: mean patient-assessed end-of-study effectiveness evaluation (0, poor; 4, excellent) by treatment group. Based on analysis of variance for each of these 3 outcomes, P<.001 for loperamide hydrochloride–simethicone vs each of the other treatment groups.